SCHEMBL24256969

SCHEMBL24256969

CCCc1nc2sc3c(NCCCc4ccc(OC)c(OC)c4)ncnc3c2c2c1CCC2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.46
HTT P42858 5/20 0.46
RAD52 P43351 3/20 0.46
MAPT P10636 3/20 0.46
MAPK1 P28482 3/20 0.46
IDE P14735 1/20 0.46
UBE2N P61088 1/20 0.46
POLB P06746 6/20 0.44
ALDH1A1 P00352 5/20 0.44
KMT2A Q03164 4/20 0.44
NPSR1 Q6W5P4 2/20 0.44
RXFP1 Q9HBX9 3/20 0.44
OPRK1 P41145 1/20 0.44
NPC1 O15118 2/20 0.43
GALR3 O60755 2/20 0.43
NR2F2 P24468 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 4/20 0.42
RECQL P46063 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24256356 0.95 NPC1 (0.48) KDM4EHTTRAD52MAPTMAPK1
SCHEMBL24256706 0.94 NPC1 (0.49) KDM4EHTTRAD52MAPTMAPK1
SCHEMBL24256703 0.91 POLB (0.47) KDM4EHTTRAD52MAPTMAPK1
SCHEMBL24256696 0.91 CHRM4 (0.48) KDM4EHTTRAD52MAPTMAPK1
SCHEMBL24256615 0.86 KDM4E (0.44) KDM4EHTTRAD52MAPTMAPK1
SCHEMBL24256693 0.85 KDM4E (0.46) KDM4EHTTRAD52MAPTMAPK1
SCHEMBL24256699 0.84 KDM4E (0.49) KDM4EHTTRAD52MAPTMAPK1
SCHEMBL24256967 0.83 ALDH1A1 (0.47) KDM4EHTTRAD52MAPTMAPK1
SCHEMBL24256352 0.82 POLB (0.51) KDM4EHTTRAD52MAPTMAPK1
SCHEMBL24256689 0.81 ALDH1A1 (0.48) KDM4EHTTRAD52MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-11-16 US disclosed
WO-2022035806-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365583-A1 FUSED TRICYCLIC PYRIMIDINE-THIENO-PYRIDINE SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP30, USP8 KDM4E 1927/4885HTT 2169/4885RAD52 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.